Drew Moghanaki

Dr. Drew Moghanaki


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2016 in Seminars in Radiation Oncology
Verified
Journal Article
Closed access
DMDrew Moghanaki
Drew Moghanaki
BTBaris Turkbey
Baris Turkbey
NVNeha Vapiwala
Neha Vapiwala
BEBehfar Ehdaie
Behfar Ehdaie
SFSteven J. Frank
Steven J. Frank
MHMukesh Harisinghani
Mukesh Harisinghani

24 December 2025 in Journal of the American Association of Nurse Practitioners
Verified
Journal Article
Open access
LCLisa Carter-Bawa
Lisa Carter-Bawa
TWTimothy J. Williamson
Timothy J. Williamson
NANancy Alvey
Nancy Alvey
ABAbbie L. Begnaud
Abbie L. Begnaud
DBDannell Boatman
Dannell Boatman
JSJamie L. Studts
Jamie L. Studts
Lung cancer remains the leading cause of cancer-related mortality in the United States, yet profound advances in screening, diagnosis, treatment, and survivorship have redefined what is possible for patients. Despite this progress, nihilism, fatalism, and stigma continue to shape public and professional perceptions, discouraging screening and delaying help-seeking. Nurse practitioners occupy a central and trusted position across the lung cancer continuum and are uniquely equipped to counter these barriers through compassionate, stigma-informed communication. This perspective article synthesizes current evidence to illuminate how nurse practitioners can translate empathy, equity, and behavioral science into tangible practice actions that reduce stigma and nihilism and instill compassion and hope. Key strengths—language, empathy, tobacco treatment integration, social context awareness, community engagement, and hope—form the “Permission to Hope” framework. By leveraging these strengths, nurse practitioners can transform everyday interactions into opportunities to rebuild trust, improve screening participation, and redefine what survivorship means in lung cancer care.

15 April 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
SKSameera Kumar
Sameera Kumar
SCSteven Chmura
Steven Chmura
CRClifford Robinson
Clifford Robinson
SLSteven Lin
Steven Lin
SGShirish M. Gadgeel
Shirish M. Gadgeel
DMDrew Moghanaki
Drew Moghanaki
Importance: The COVID-19 pandemic is currently accelerating. Patients with locally advanced non-small cell lung cancer (LA-NSCLC) may require treatment in locations where resources are limited and the prevalence of infection is high. Patients with LA-NSCLC frequently present with comorbidities that increase the risk for severe morbidity and mortality from COVID-19. These risks may be further increased by treatments for LA-NSCLC. Observation: We present expert thoracic oncology multidisciplinary (radiation oncology, medical oncology, surgical oncology) consensus of alternative strategies for the treatment of LA-NSCLC during a pandemic. The overarching goals of these approaches are to reduce the number of visits to a healthcare facility, reduce the risk of SARS-CoV-2 exposure, and attenuate the immunocompromising effects of lung cancer therapies. Patients with resectable disease can be treated with definitive non-operative management if surgical resources are limited or the risks of perioperative care are high. Non-operative options include chemotherapy, chemoimmunotherapy, and radiation therapy with sequential schedules. The order of treatments may be based on patient factors and clinical resources. Whenever radiation therapy is delivered without concurrent chemotherapy, hypofractionated schedules are appropriate. For patients who are confirmed to have COVID-19, usually cancer therapies may be withheld until symptoms have resolved with negative viral test results. Conclusions and Relevance: The risk of severe treatment-related morbidity and mortality is significantly elevated for patients undergoing treatment for LA-NSCLC during the COVID-19 pandemic. Adapting alternative treatment strategies as quickly as possible may save lives and should be implemented through communication with the multidisciplinary cancer team.